KSE - Delayed Quote KRW
SK Biopharmaceuticals Co., Ltd. (326030.KS)
104,100.00
-800.00
(-0.76%)
At close: 3:30:30 PM GMT+9
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
547,596,283.21
547,596,283.21
354,891,555.52
246,179,120.02
418,644,529.12
Cost of Revenue
43,100,914.32
43,100,914.32
34,082,497.21
37,768,133.59
22,335,994.40
Gross Profit
504,495,368.89
504,495,368.89
320,809,058.31
208,410,986.43
396,308,534.72
Operating Expense
408,155,709
408,155,709
358,331,255
339,489,015
301,350,334
Operating Income
96,339,659.89
96,339,659.89
-37,522,196.69
-131,078,028.57
94,958,200.72
Net Non Operating Interest Income Expense
-536,323.31
-536,323.31
1,037,850.71
3,038,234.68
1,395,928.51
Pretax Income
72,595,756.15
72,595,756.15
-43,857,762.62
-142,468,863.95
71,276,548.23
Tax Provision
-154,377,679.21
-154,377,679.21
-8,478,274.12
-3,037,986.27
6,430,907.91
Net Income Common Stockholders
240,738,037.87
240,738,037.87
-32,882,849.24
-139,430,878
64,845,640
Basic EPS
3.07k
--
-420.00
-1.78k
828.00
Diluted EPS
3.07k
--
-420.00
-1.78k
828.00
Basic Average Shares
78,314.26
--
78,292.50
78,331.95
78,315.99
Diluted Average Shares
78,314.26
--
78,292.50
78,331.95
78,315.99
Total Operating Income as Reported
96,339,659.52
96,339,659.52
-37,522,197.04
-131,078,028.19
94,958,200.24
Total Expenses
451,256,623.32
451,256,623.32
392,413,752.21
377,257,148.59
323,686,328.40
Net Income from Continuing & Discontinued Operation
240,738,037.87
240,738,037.87
-32,882,849.24
-139,430,878
64,845,640
Normalized Income
247,875,145.43
247,875,145.43
-25,270,165.47
-127,045,850.86
66,687,197.99
Interest Income
10,146,197
10,146,197
9,317,460
6,754,760
2,342,913
Interest Expense
10,682,521
10,682,521
8,279,609
3,716,526
946,984
Net Interest Income
-536,323.31
-536,323.31
1,037,850.71
3,038,234.68
1,395,928.51
EBIT
83,278,277.15
83,278,277.15
-35,578,153.62
-138,752,337.95
72,223,532.23
EBITDA
100,705,843.15
100,705,843.15
-20,260,709.62
-125,768,599.95
83,865,360.23
Reconciled Cost of Revenue
43,100,914.32
43,100,914.32
34,082,497.21
37,768,133.59
22,335,994.40
Reconciled Depreciation
17,427,566
17,427,566
15,317,444
12,983,738
11,641,828
Net Income from Continuing Operation Net Minority Interest
240,738,037.87
240,738,037.87
-32,882,849.24
-139,430,878
64,845,640
Total Unusual Items Excluding Goodwill
-9,390,931
-9,390,931
-9,436,973
-12,654,878
-2,024,190
Total Unusual Items
-9,390,931
-9,390,931
-9,436,973
-12,654,878
-2,024,190
Normalized EBITDA
110,096,774.15
110,096,774.15
-10,823,736.62
-113,113,721.95
85,889,550.23
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-2,253,823.44
-2,253,823.44
-1,824,289.23
-269,850.86
-182,632.01
12/31/2021 - 7/2/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade